Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy

Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. This is an open-label retrospective cohort study of 993...

Full description

Saved in:

Bibliographic Details
Published in:	PloS one Vol. 6; no. 2; p. e16664
Main Authors:	Castillo-Trivino, Tamara, Mowry, Ellen M., Gajofatto, Alberto, Chabas, Dorothee, Crabtree-Hartman, Elizabeth, Cree, Bruce A., Goodin, Douglas S., Green, Ari J., Okuda, Darin T., Pelletier, Daniel, Zamvil, Scott S., Vittinghoff, Eric, Waubant, Emmanuelle
Format:	Journal Article
Language:	English
Published:	United States Public Library of Science 03.02.2011 Public Library of Science (PLoS)
Subjects:	Adult Algorithms Analysis Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Autoimmune diseases Care and treatment Chemotherapy, Adjuvant Clinical trials Cohort analysis Cohort Studies Disease Progression Drug dosages Drug Substitution - methods Drugs Female Humans Immunologic Factors - therapeutic use Immunomodulation Immunosuppressive agents Immunosuppressive Agents - therapeutic use Interferon Leukemia Male Medical research Medicine Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Natalizumab Neurology Patients Poisson density functions Recurrence Regression analysis Retrospective Studies Rheumatoid arthritis Statistical analysis Switching Therapy United States > US San Francisco California California
ISSN:	1932-6203, 1932-6203
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!